Article
Chemistry, Multidisciplinary
Juan Wang, Zeyuan Cao, Panpan Wang, Xiao Zhang, Jianxia Tang, Yifan He, Zhiqing Huang, Xueli Mao, Songtao Shi, Xiaoxing Kou
Summary: The study demonstrates that apoEVs can induce multiple myeloma cell apoptosis and inhibit tumor growth, suggesting a potential therapeutic use of apoEVs for MM treatment.
Review
Oncology
Raquel Lopes, Bruna Velosa Ferreira, Joana Caetano, Filipa Barahona, Emilie Arnault Carneiro, Cristina Joao
Summary: Multiple myeloma is a hematological malignancy arising from the proliferation of tumor antibody-producing cells in the bone marrow. Immunotherapy is a form of cancer treatment that aims to stimulate the immune system to fight back tumor cells, but has not yet been able to cure multiple myeloma completely.
Review
Oncology
Danai Dima, Dongxu Jiang, Divya Jyoti Singh, Metis Hasipek, Haikoo S. Shah, Fauzia Ullah, Jack Khouri, Jaroslaw P. Maciejewski, Babal K. Jha
Summary: Multiple myeloma (MM) is a complex hematologic malignancy that remains incurable despite several therapeutic advancements. This review discusses the current treatment paradigm of MM and highlights promising future approaches.
Review
Oncology
Jennifer Sun, Chaelee Park, Nicole Guenthner, Shannon Gurley, Luna Zhang, Berit Lubben, Ola Adebayo, Hannah Bash, Yixuan Chen, Mina Maksimos, Barbara Muz, Abdel Kareem Azab
Summary: MM is a cancer of plasma cells in the bone marrow, with the tumor microenvironment playing a critical role in disease progression. TAMs in the TME have been found to support tumor survival and chemoresistance, highlighting the importance of exploring macrophage-targeted immunotherapy in MM treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Hematology
Federico Vozella, A. Siniscalchi, M. Rizzo, T. Za, G. Antolino, U. Coppetelli, A. Piciocchi, A. Andriani, O. Annibali, L. De Rosa, G. Cimino, G. La Verde, V. De Stefano, M. Cantonetti, T. Caravita di Toritto, M. T. Petrucci
Summary: The study aimed to determine the efficacy and toxicity profile of daratumumab in real-world patients with relapsed/refractory multiple myeloma, showing that daratumumab monotherapy is an effective treatment with a favorable safety profile for heavily pre-treated and refractory patients.
ANNALS OF HEMATOLOGY
(2021)
Review
Immunology
Leora S. Boussi, Zachary M. Avigan, Jacalyn Rosenblatt
Summary: Despite advances in treatment for multiple myeloma, understanding the mechanisms of immune evasion and resistance to therapy is critical for developing more effective treatments. Cellular adoptive therapy, particularly CAR T cell therapy, has shown promising results in refractory cases and may be a viable option for treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Fabiola De Luca, Alessandro Allegra, Carla Di Chio, Santo Previti, Maria Zappala, Roberta Ettari
Summary: Multiple myeloma is an incurable hematologic cancer characterized by immunological alterations in myeloid cells and lymphocytes. The current first-line therapy involves chemotherapy, but there is a high relapse rate and refractory MM cases. New monoclonal antibodies (Mab) including daratumumab, isatuximab, and elotuzumab, along with bispecific antibodies and CAR T cell therapy, have shown promise in immunotherapy for MM. CD38 (daratumumab and isatuximab), SLAM7 (elotuzumab) and BCMA (belantamab mafodotin) are the main antibody targets for MM treatment. Although MM is still incurable, combining the available drugs offers hope for improving outcomes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Raquel Lopes, Joana Caetano, Bruna Ferreira, Filipa Barahona, Emilie Arnault Carneiro, Cristina Joao
Summary: The interaction between multiple myeloma and immune cells in the bone marrow microenvironment is considered a key aspect of this hematological disease. Understanding how myeloma cells disrupt immune homeostasis is crucial in developing effective treatments, particularly through immunotherapy. Ongoing pre-clinical studies are focused on targeting immune populations within the bone marrow niche, aiming to improve outcomes for patients with multiple myeloma.
Review
Immunology
Zhaoyun Liu, Chun Yang, Xiaohan Liu, Xintong Xu, Xianghong Zhao, Rong Fu
Summary: Multiple myeloma, as an incurable hematological malignancy, is affected by both somatic genetic mutations and the immunosuppressive microenvironment. Despite the discovery of immunotherapy, there are still challenges in achieving effective treatment and preventing disease recurrence. This review discusses therapeutic strategies to enhance the specific anti-tumor immune response by activating the immunogenicity of MM cells and provides new ideas for future myeloma therapy.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Leona Yamamoto, Nicola Amodio, Annamaria Gulla, Kenneth Carl Anderson
Summary: Multiple myeloma is an incurable malignancy characterized by plasma cell growth within a permissive bone marrow microenvironment. Targeting the immunosuppressive bone marrow niche to restore effective anti-MM immunity has shown promising potential, with approaches focusing on enhancing T cell effector function and increasing MM clone immunogenicity to improve therapeutic outcomes.
FRONTIERS IN ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Antonio G. Solimando, Markus Krebs, Vanessa Desantis, Donatello Marziliano, Ingrid Catalina Caradonna, Arcangelo Morizio, Antonella Argentiero, Endrit Shahini, Max Bittrich
Summary: Multiple myeloma (MM) is a cancerous condition characterized by the proliferation of plasma cells in the bone marrow, leading to multiple bone lesions. Over the past two decades, significant advancements have been made in the development of novel therapeutics for MM, improving patient outcomes and overall survival. These advancements include thalidomide and its derivatives, proteasome inhibitors, monoclonal antibodies, and CAR-T-based strategies, which target neoplastic plasma cells and the tumor microenvironment.
Review
Oncology
Christine Greil, Monika Engelhardt, Juergen Finke, Ralph Waesch
Summary: Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a controversial treatment for multiple myeloma (MM) due to its associated toxicity. However, recent data suggests that it should be considered in young patients without comorbidities, particularly in high-risk cases as part of a tandem approach. Prospective studies, especially those involving new immunotherapeutic approaches, are needed to further evaluate its efficacy.
Review
Biochemistry & Molecular Biology
Emma Verheye, Jesus Bravo Melgar, Sofie Deschoemaeker, Geert Raes, Anke Maes, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Damya Laoui, Kim De Veirman
Summary: Immunotherapeutic approaches, particularly DC-based immunotherapy, have revolutionized treatment in multiple myeloma. However, long-term and durable responses in patients have been limited, potentially due to the source of DCs and the immunosuppressive bone marrow microenvironment. This review summarizes the development and characteristics of DCs in the bone marrow niche, addresses the known deficiencies in MM, and provides strategies to improve the efficacy of DC vaccines.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Immunology
Zehua Wang, Chen Chen, Lei Wang, Yongxu Jia, Yanru Qin
Summary: This article introduces CAR-T cell therapy for multiple myeloma, discusses the challenges faced by CAR-T therapy, and innovative methods to overcome resistance and toxic side effects. The article also mentions B Cell Maturation Antigen (BCMA) as the most successful target for CAR-T therapy and other potential targets being studied in clinical trials.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Federico Vozella, Francesca Fazio, Gianfranco Lapietra, Maria T. Petrucci, Giovanni Martinelli, Claudio Cerchione
Summary: In recent years, the treatment landscape for multiple myeloma patients has seen significant advancements with the introduction of next-generation proteasome inhibitors, immunomodulatory derivatives, and monoclonal antibodies. Monoclonal antibodies offer a promising new approach with immune-based mechanisms that induce durable responses and have shown effectiveness in heavily pretreated or double refractory patients. These antibodies work through various pathways, including ADCC, ADCP, CDC, and the induction of signals on cell effectors, targeting key molecular pathways involved in the survival of malignant plasma cells.
Article
Oncology
N. Jain, H. Zhu, T. Khashab, Q. Ye, B. George, R. Mathur, R. K. Singh, Z. Berkova, J. F. Wise, F. K. Braun, X. Wang, K. Patel, Zy Xu-Monette, J. Courty, K. H. Young, L. Sehgal, F. Samaniego
Article
Biochemistry & Molecular Biology
Tara H. W. Dobson, Rong-Hua Tao, Jyothishmathi Swaminathan, Shinji Maegawa, Shavali Shaik, Javiera Bravo-Alegria, Ajay Sharma, Bridget Kennis, Yanwen Yang, Keri Callegari, Amanda R. Haltom, Pete Taylor, Mari Kogiso, Lin Qi, Soumen Khatua, Stewart Goldman, Rishi R. Lulla, Jason Fangusaro, Tobey J. MacDonald, Xiao-Nan Li, Cynthia Hawkins, Veena Rajaram, Vidya Gopalakrishnan
Article
Hematology
Junling Zhuang, Fazal Shirazi, Ram Kumar Singh, Isere Kuiatse, Hua Wang, Hans C. Lee, Zuzana Berkova, Allison Berger, Marc Hyer, Nibedita Chattopadhyay, Sakeena Syed, Judy Qiuju Shi, Jie Yu, Vaishali Shinde, Stephen Tirrell, Richard Julian Jones, Zhiqiang Wang, R. Eric Davis, Robert Z. Orlowski
Article
Oncology
Bridget A. Kennis, Keith A. Michel, William B. Brugmann, Alvaro Laureano, Rong-Hua Tao, Srinivas S. Somanchi, Samuel A. Einstein, Javiera B. Bravo-Alegria, Shinji Maegawa, Andrew Wahba, Simin Kiany, Nancy Gordon, Lucia Silla, Dawid Schellingerhout, Soumen Khatua, Wafik Zaky, David Sandberg, Laurence Cooper, Dean A. Lee, James A. Bankson, Vidya Gopalakrishnan
JOURNAL OF NEURO-ONCOLOGY
(2019)
Correction
Oncology
Bridget A. Kennis, Keith A. Michel, William B. Brugmann, Alvaro Laureano, Rong-Hua Tao, Srinivas S. Somanchi, Samuel A. Einstein, Javiera B. Bravo-Alegria, Shinji Maegawa, Andrew Wahba, Simin Kiany, Nancy Gordon, Lucia Silla, Dawid Schellingerhout, Soumen Khatua, Wafik Zaky, David Sandberg, Laurence Cooper, Dean A. Lee, James A. Bankson, Vidya Gopalakrishnan
JOURNAL OF NEURO-ONCOLOGY
(2019)
Letter
Hematology
Elisabet E. Manasanch, Jatin J. Shah, Hans C. Lee, Donna M. Weber, Sheeba K. Thomas, Behrang Amini, Jasper Olsem, Brandon Crumpton, Ashley Morphey, Zuzana Berkova, Lei Feng, Robert Z. Orlowski
Letter
Hematology
Elisabet E. Manasanch, Preetesh Jain, Wendy Chen, Onyeka Oriabure, Maria Badillo, Lei Feng, Zuzana Berkova, Robert Z. Orlowski, Michael Wang
AMERICAN JOURNAL OF HEMATOLOGY
(2020)
Letter
Oncology
Elisabet E. Manasanch, Victor Mulanovich, Joanna-Grace Manzano, Maria Susan Gaeta, Melody Becnel, Gregory P. Kaufman, Hans C. Lee, Behrang Amini, Sheeba K. Thomas, Swaminathan P. Iyer, Donna M. Weber, Zuzana Berkova, Christopher R. Flowers, Robert Z. Orlowski, Krina K. Patel
LEUKEMIA & LYMPHOMA
(2020)
Article
Multidisciplinary Sciences
Fazal Shirazi, Richard J. Jones, Ram K. Singh, Jianxuan Zou, Isere Kuiatse, Zuzana Berkova, Hua Wang, Hans C. Lee, Samuel Hong, Larry Dick, Nibedita Chattopadhyay, Robert Z. Orlowski
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2020)
Article
Oncology
Rong-Hua Tao, Masato Kobayashi, Yuanzheng Yang, Eugenie S. Kleinerman
Summary: Exercise promotes the migration of BM stem cells into the heart to repair cardiac vessels damaged by Dox and inhibits Hippo-YAP signaling-mediated cardiomyocyte apoptosis. These findings suggest that exercise can be used as an intervention to decrease Dox-induced cardiotoxicity.
Article
Engineering, Multidisciplinary
Cheng Chi, Dan Wang, Ronghua Tao, Zhentao Yu
Summary: This paper proposes an error calibration method for the magnetic gradient tensor system. By establishing an error calibration model for the single fluxgate magnetometer and using the orthogonal Procrustes problem to calibrate misalignment errors, simulations and experiments demonstrate that this method greatly improves the measurement accuracy of the magnetic gradient tensor system.
MATHEMATICAL PROBLEMS IN ENGINEERING
(2023)
Meeting Abstract
Oncology
Rong-Hua Tao, Masato Kobayashi, Fei Wang, Yuanzheng Yang, Eugenie S. Kleinerman
Article
Hematology
Elisabet E. Manasanch, Guangchun Han, Rohit Mathur, Yun Qing, Zheng Zhang, Hans Lee, Donna M. Weber, Behrang Amini, Zuzana Berkova, Karina Eterovic, Shaojun Zhang, Jianhua Zhang, Xingzhi Song, Xizeng Mao, Margaret Morgan, Lei Feng, Veera Baladandayuthapani, Andrew Futreal, Linghua Wang, Sattva S. Neelapu, Robert Z. Orlowski
Meeting Abstract
Hematology
Fazal Shirazi, Richard J. Jones, Isere Kuiatse, Zuzana Berkova, Hua Wang, Hans C. Lee, Samuel Hong, Ram Kumar Singh, Lawrence Robert Dick, Nibedita Chattopadhyay, Robert Z. Orlowski
Article
Oncology
Haiwen Ni, Fazal Shirazi, Veerabhadran Baladandayuthapani, Heather Lin, Isere Kuiatse, Hua Wang, Richard J. Jones, Zuzana Berkova, Yasumichi Hitoshi, Stephen M. Ansell, Steven P. Treon, Sheeba K. Thomas, Hans C. Lee, Zhiqiang Wang, R. Eric Davis, Robert Z. Orlowski
CLINICAL CANCER RESEARCH
(2018)